Agenus Inc. (AGEN)
NASDAQ
Closed
Aug 24, 2026
Day's Range
7.6052 wk Range
2.71Profile - AGEN - Agenus Inc.
Profile
Mic Code
XNCM
Sector
Healthcare
Industry
Biotechnology
Employees
81
Agenus Inc. is a clinical-stage biotechnology company focused on immuno-oncology and the development of therapies designed to activate the immune system against cancer. The company’s current work centers on antibody-based therapeutics, immune checkpoint modulators, cell therapies, vaccines, and vaccine adjuvants, supported by proprietary discovery and manufacturing capabilities. Its pipeline includes programs intended for solid tumors and other difficult-to-treat cancers, with activities spanning research, clinical development, and translational science. Agenus also operates through its subsidiaries and technology platforms to support antibody discovery and cell-therapy development, reflecting a vertically integrated model in biotechnology. Headquartered in Lexington, Massachusetts, and founded in 1994, Agenus serves as a development-stage company within the broader life sciences market, where it contributes to cancer immunotherapy innovation and clinical research.
Profile Details
Type
Common Stock
Address
3 Forbes Road
City
Lexington
State
MA
Zip
02421-7305
Country
United States
Phone
781 674 4400
Key Executives - AGEN - Agenus Inc.
Key executives
Cross Listings - AGEN - Agenus Inc.
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
